Posted by Michael Wonder on 27 May 2026
ICER to assess treatments for Friedreich’s ataxia
26 May 2026 - Report will be subject of New England CEPAC meeting in January 2027; draft scoping document open to public comment until 16 June 2026.
The ICER announced today that it will assess the comparative clinical effectiveness and value of nomlabofusp (Larimar Therapeutics) and omaveloxolone (Skyclarys, Biogen) for Friedreich’s ataxia.
